Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099998 | 0.84 | L3MBTL1 (0.53) | KMOL3MBTL1MEN1ALDH1A1GAA | |
| SCHEMBL16186527 | 0.84 | L3MBTL1 (0.74) | L3MBTL1MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL16176497 | 0.82 | KMO (0.76) | KMOCYP1A2CYP3A4CYP2C19TSPO | |
| SCHEMBL25307601 | 0.81 | L3MBTL1 (0.58) | L3MBTL1MEN1ALDH1A1GAAPKM | |
| SCHEMBL13099996 | 0.81 | CDYL2 (0.64) | KMOL3MBTL1TP53TSPO | |
| SCHEMBL10444126 | 0.78 | ALDH1A1 (0.64) | L3MBTL1MEN1ALDH1A1KMT2A | |
| SCHEMBL29456233 | 0.75 | KDM4E (0.48) | ALDH1A1GRIN1GRIN2B | |
| SCHEMBL3780636 | 0.75 | KDM4E (0.48) | ALDH1A1GRIN1GRIN2B | |
| SCHEMBL12002100 | 0.74 | KDM4E (0.51) | L3MBTL1CYP1A2MEN1ALDH1A1KMT2A | |
| SCHEMBL10621865 | 0.74 | CBX7 (0.47) | KMOMEN1KMT2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8937087-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2015-01-20 | — | — | US | disclosed |
| WO-2014171528-A1 | HETEROCYCLIC ACETIC ACID AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD1, DRD2, OPRD1 | KMO 1970/4885L3MBTL1 2687/4885CYP1A2 1035/4885 |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD2, DRD1, OPRD1 | KMO 2179/4885L3MBTL1 2901/4885CYP1A2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.